Ozempic (semaglutide) has gained widespread recognition for its effectiveness in controlling blood glucose levels in patients affected by type 2 diabetes
Phase 3 Trial Deep Dive I pulled the primary publications for each pivotal trial and summarized the design and findings below
nejm.org/doi/full/10.10 Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure)
Novakova K, Kummer O, Bouitbir J, Stoffel SD, Hoerler-Koerner U, Bodmer M, Roberts P, Urwyler A, Ehrsam R, Krhenbhl S
282 (Part 1): 305306